Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

Two straight years of growth for Pfizer Inc.’s consumer health product sales aren't giving it second thoughts about moving the business into a joint venture with GlaxoSmithKline PLC.

Instead, those results, following a flat year in 2016 and a dip in 2015, confirm Pfizer's view of consumer health...